The eFlow®rapid nebuliser system is a strong companion for the daily inhalation therapy of chronic diseases of the lower airways. So that you have more time to enjoy the beautiful things in life.
The eFlow®rapid ensures high lung deposition of the generated aerosol, which enables the nebulised solution to be as effective as possible.2,3
The nebuliser system is lightweight, small and mobile and can be powered by battery or mains electricity – for silent inhalation therapy wherever you are.
The eFlow® Technology of the aerosol head enables short nebulisation times.1,4
... thanks to easy cleaning and disinfection of the nebuliser handset.
Easy to use
The device guides the user with a visible display.
Users worldwide benefit from the clinically tested eFlow® Technology
The eFlow®rapid nebuliser system has two main components: the eBase® Controller for power supply and device control and the eFlow®rapid nebuliser handset.
It produces the respirable aerosols required for therapy which are quickly transported deep into the lungs.
Proper use is important to ensure effective treatment. This is what you should consider when inhaling with the eFlow®rapid.
The eFlow®rapid is driven by high-quality technology. Regular hygiene procedures are required to ensure it is always at its best.
The eFlow®rapid nebuliser system features a wide range of applications. The eFlow®rapid nebuliser handset is suitable for the therapy of the lower airways with the most common inhalation solutions and suspensions. It is used for the nebulisation of 5:
Please note the warnings in the package leaflet of the specific solution, suspension or medication.
A medication-specific nebuliser handset is required for certain antibiotics or medications. This is supplied with the medication.
The eBase® Controller is supplied as standard as part of the eFlow®rapid nebuliser system. However, it can also be used for the following nebuliser handsets for inhalation of certain medicines.
1 Short inhalation time* for more leisure time and better quality of life.
*Buttini F et al. Int J Pharm 2016; 502(1-2):242-8
2 Beck-Broichsitter, M. J Pharm Sci, 2017. 106(8): p. 2168-2172
3 Beck-Broichsitter M et al. Eur J Pharm Biopharm 2014; 87(3): 524-9
4 Naehrig S et al. Eur J Med Res 2011; 16(2): 63-6
5 Online surveys carried out by PARI among medical professionals in paediatric CF centres in Germany (October to December 2019) and the United Kingdom (November to December 2018); 54 participants (see also Ollmann-Selinger, M. et al., ERS 2020, Abstract no. 2333; poster is available on request from PARI)